Patent Foramen Ovale Benefits From Transcatheter ClosurePatent Foramen Ovale Benefits From Transcatheter Closure
Transcatheter closure of patent foramen ovale (PFO) is superior to medical management for preventing recurrent vascular events, but not all closure devices are equal. Reuters Health Information
Patent foramen ovale (PFO) is a potential cause of cryptogenic cerebrovascular events (c-CVEs). A score has been developed to identify stroke-related versus incidental PFO in c-CVEs. The Risk of Paradoxical Embolism (RoPE) score indicates that otherwise healthy young adults with a high score are likely to have pathogenic PFO.1 –3 Until recently, there was a lack of evidence for routine closure of PFO in patients who suffered from c-CVEs.4–6 However, three recent randomized studies showed a benefit of transcatheter PFO closure compared with medical therapy.
CONCLUSION: Compared with drug therapy, PFO closure reduced the risk of recurrent stroke among patients with a risk score of ≥2 and reduced the incidence of serious bleeding without increasing the risk of new-onset atrial fibrillation or atrial flutter. PMID: 32394019 [PubMed - as supplied by publisher]
ConclusionThis is a report about acromicric dysplasia with stiff skin syndrome ‐like severe cutaneous presentation caused by a single hotspot mutation, further revealing the gene pleiotropy ofFBN1.
CONCLUSION: The results do not suggest that a patent foramen ovale intervenes in the pathophysiology of the white matter lesions observed in patients with migraine. PMID: 32390130 [PubMed - in process]
Abstract BACKGROUND: Residual shunt is observed in up to 25% of patients after patent foramen ovale (PFO) closure, but its long-term influence on stroke recurrence currently is unknown. OBJECTIVE: To investigate the association of residual shunt after PFO closure with the incidence of recurrent stroke and transient ischemic attack (TIA). DESIGN: Prospective cohort study comparing stroke or TIA recurrence in patients with and without residual shunt after PFO closure. SETTING: Single hospital center. PARTICIPANTS: 1078 consecutive patients (mean age, 49.3 years) with PFO-attributable cryptogenic ...
ConclusionsConclusions: cRoPE might help in stratification of patients with CS, allowing accurate esteem of the likelihood of PFO to be found, especially in cases when neuroimaging is inconclusive.
We present a case report of a patient with a pulmonary embolus placed on venoarterial extracorporeal membrane oxygenation who developed venous cannula migration through an undiagnosed patent foramen ovale causing an ischemic stroke due to a thrombus and requiring thrombectomy and device closure of the atrial defect.
Conclusion: VTE can be detected in patients with CS linked to PFO. While –based on the presented literature–routine screening for VTE in patients with CS linked to PFO does not appear justified, history taking, and clinical exam should consider concomitant VTE. Whenever clinically suspected, the threshold to trigger ancillary testing for VTE should be low. Among patients with an acute PE and PFO, vigilance for new neurologic deficits should be increased, with a low threshold for brain imaging.
Rationale: Patent foramen ovale (PFO) is not considered to be the main cause of stroke and is classified as the infarction of undetermined cause. The relationship between PFO and cerebral embolism is still unclear and cerebral embolism accompanied with coronary artery embolization in PFO patient is rare. In this case, we reported a patient with PFO suffered acute cerebral and myocardial infarction simultaneously, and analyzed the source of emboli and potential pathogenesis. Patient concerns: A 53-year-old female presented with chief complaints of intermittent palpitations and chest tightness for 6 years, aggravated fo...
In an updated practice advisory, the American Academy of Neurology says closure of patent foramen ovale may be recommended for some people who have had a stroke.Medscape Medical News